Lexaria Bioscience Corp. (LEXX)
| Market Cap | 30.52M |
| Revenue (ttm) | 618,117 |
| Net Income (ttm) | -3.72M |
| Shares Out | 3.00M |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $5.98 |
| Previous Close | $6.11 |
| Change ($) | -0.13 |
| Change (%) | -2.13% |
| Day's Open | 5.89 |
| Day's Range | 5.79 - 6.08 |
| Day's Volume | 97,602 |
| 52-Week Range | 3.98 - 9.46 |
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the...
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabino...
Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug d...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is plea...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten...
KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin tradin...
About LEXX
Lexaria Bioscience operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
| Industry Packaged Foods | Founded 2004 |
| CEO Christopher A. Bunka | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol LEXX |
Financial Performance
In 2020, LEXX's revenue was $384,543, an increase of 72.74% compared to the previous year's $222,610. Losses were -$4.08 million, -1.77% less than in 2019.